+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07476326

Comparing Pharmacokinetics, Safety, and Immune Response of Bmab1700 and Opdivo After Complete Surgical Removal of Stage IIB-IV Melanoma

Led by Biocon Biologics UK PLC · Updated on 2026-09-25

120

Participants Needed

46

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the pharmacokinetics similarity, safety, and immune response between Bmab1700, an intended biosimilar to nivolumab, and the United States-licensed Opdivo in participants who have had complete surgical removal of melanoma. The study focuses on adults with Stage IIB, IIC, III, or IV melanoma that has been fully resected. This phase 1 trial aims to compare these treatments as adjuvant monotherapy after surgery to understand their behavior in the body and their safety. Participants are randomly assigned to one of two groups. In the first 24 weeks Double-Blind Treatment Period, they receive intravenous infusions of either Bmab1700 or Opdivo every four weeks until disease relapse, unacceptable toxicity, or Week 20, whichever comes first. After Week 24, participants who continue in the study enter an Open-Label Treatment Period where all receive Bmab1700 every four weeks until Week 48, followed by an end-of-study visit at Week 52. Throughout the study, participants undergo regular assessments including blood sampling for drug concentration and immune response measures, monitoring for adverse events, and physical exams. Researchers measure drug levels over time, immune antibody development, and safety outcomes to evaluate the treatments. The total participation lasts up to 52 weeks, with careful monitoring to track treatment effects and participant health.

CONDITIONS

Brief Title

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

Research Team

D

Dr. Gursharan Singh, MBBS; PhD Pharm Med; LLM-IP

R

Rajesh CN

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here